イトウ トモキ   ITO TOMOKI
  伊藤 量基
   所属   関西医科大学  内科学第一講座
   職種   教授
論文種別 原著(症例報告除く)
言語種別 英語
査読の有無 査読あり
表題 Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
掲載誌名 正式名:Transplantation and cellular therapy
略  称:Transplant Cell Ther
ISSNコード:26666375/26666367
掲載区分国外
巻・号・頁 27(8),pp.660.e1-660.e8
著者・共著者 Hotta M, Satake A, Yoshimura H, Fujita S, Katayama Y, Ota S, Hanamoto H, Oyake T, Ito S, Okada M, Nakanishi T, Ito T, Ishii K, Nomura S.
発行年月 2021/08
概要 Early prediction of nonrelapse mortality (NRM) in patients undergoing allogeneic
hematopoietic stem cell transplantation (allo-HSCT) based on the results of
laboratory tests is challenging. Thus, there is a need to evaluate biomarkers
for prediction of NRM, a major problem that offsets the advantages of allo-HSCT.
We tested the validity and efficacy of 2 plasma biomarkers, ST2 and Reg3α, based
on the Mount Sinai Acute GVHD International Consortium (MAGIC) algorithm, for
early prediction of NRM in Japanese patients who underwent allo-HSCT. We
conducted a multicenter retrospective study to analyze the clinical data of 112
patients with hematopoietic malignancies who underwent allo-HSCT. Patient blood
samples on day 7 after allo-HSCT were obtained from 6 hospitals. The plasma
concentrations of ST2 and Reg3α were used to calculate a 6-month NRM risk score.
Based on the scores determined in this study, we identified 64 low-risk patients
and 48 high-risk patients for the 6-month NRM. The cumulative incidence of
6-month NRM was 29.2% in the high-risk group and 10.9% in the low-risk group (P
< .05). The cumulative incidence of relapse mortality was similar in the
high-risk and low-risk patients. The biomarker score was predictive in patients
with an unrelated donor, an HLA-mismatched donor, high/very high Disease Risk
Index, and Hematopoietic Cell Transplantation Comorbidity Index ≥1. Multivariate
analysis identified high biomarker probability as a significant predictor of
NRM. The MAGIC algorithm based on blood samples obtained at 7 days after
allo-HSCT can identify individuals at high risk for NRM among patients with
clinical risk factors for NRM in a Japanese cohort.
DOI 10.1016/j.jtct.2021.04.025
PMID 33989832